ILMN Stock Price Today (October 2026) — Illumina, Inc. Analysis & Key Metrics 2026-10-07
Illumina, Inc. (ILMN) is trading at $267.76, down 2.11% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $210.65 (21.3% downside).
- Volatility is high (51.55% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.40% YoY) alongside competitive pressures in the Diagnostics & Research space.
ILMN Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Illumina, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $41.79B
P/E Ratio
Forward P/E: 35.04
Revenue Growth
Year over Year
Analyst Target
-21.3% downside from target
Key Investor Questions About ILMN
What investors need to know before buying
Based on current market data, ILMN presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 57.19)
- Fundamentals say: Looking solid (debt and growth supportive)
ILMN's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ILMN investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $2.53B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, ILMN stock traded between $88.00 and $280.17 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 51.55% annualized volatility and β=1.07, the stock exhibits moderate correlation to market moves—making ILMN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Illumina (ILMN) Tests Valuation As Russell Index Removal Forces A Fresh Look
Index removal puts Illumina in focus Illumina (ILMN) has been removed from the Russell Small Cap Value Index, an index reshuffle that can prompt mechanical selling and raise fresh questions about how the stock is being valued today. The index removal comes at a time when Illumina’s momentum is already strong, with a 1-day share price return of 7.25%, a 30-day share price return of 21.82% and a year-to-date share price return of 103.87%. These feed into a 1-year total shareholder return of...
Illumina Stock Surges 94.9% YTD: What's Behind the Rally?
ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.
Illumina Stock Is Up 133% This Year. Here’s Where It Could Go Further.
Key TakeawaysYear-Long Surge: Illumina stock has climbed 133% over the past year, closing at $240 on September 18, 2026, up from roughly $103 twelve months earlier. Street Split: Illumina stock carries 7 buy ratings, 4 outperforms, 6 holds, 3 underperforms and 1 sell, and the $203 mean target now sits 15% below where shares trade, a reversal from a year ago when the target sat above the price.
S&P Dow Jones Indices CEO on Index Restructuring
Catherine Clay, CEO of S&P Dow Jones Indices, discusses the upcoming S&P reconstitution and rebalance, noting that the process is fully transparent and routine. She says market participants already know which names are entering and leaving the index, including Bloom Energy, Illumina and Everpure joining the S&P this month, and have ample time to adjust portfolios accordingly. She speaks with Romaine Bostick & Tyler Kendall on "The Close."
Dear Illumina Stock Fans, Mark Your Calendars for September 21
Illumina stock is joining the S&P 500 on Sept. 21. Here's why that matters, what's fueling growth, and what investors should watch next.
Dear Everpure Stock Fans, Mark Your Calendars for September 21
Everpure stock is joining the S&P 500 on Sept. 21. Here's what's changing, why it matters, and what's driving Everpure's growth this year.
3 Stocks Soon Joining the S&P 500
The S&P 500 is set for another shakeup, with Bloom Energy (BE), Everpure (P), and Illumina (ILMN) all joining in the next quarterly rebalancing near the end of September.
ILMN Stock Keeps Climbing. Should You Climb On?
A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Bloom Energy Stock Rallies on News of S&P 500 Addition
Shares of Bloom Energy are surging on the news that the company is set to join the S&P 500.
Explore More Analysis for ILMN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Illumina, Inc.
Illumina, Inc. (ILMN) is currently trading at $267.76. The RSI (14-day) is at 57.2, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $210.65 implies 21.3% downside from current levels. Volatility is high at 51.5% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Illumina, Inc. (ILMN): The trailing P/E ratio is 39.14, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 35.04, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 3.23, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 11.08. Price-to-Sales is 7.00. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 20 analysts covering ILMN, the consensus price target is $210.65. This represents a 21.3% downside from the current price of $267.76. The range spans from a low target of $113.00 to a high target of $305.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Illumina, Inc. (ILMN) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Illumina, Inc. (ILMN) investors include: 1. High volatility (51.5% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (11.5% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Illumina, Inc.'s (ILMN) current debt and financial health profile: Total debt stands at $2.53B. The debt-to-equity ratio is 0.89x, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.80, indicating strong short-term liquidity. The quick ratio is 1.25. The company holds $1.17B in cash and equivalents. Free cash flow is positive at $797.63M, providing a cushion for debt servicing and shareholder returns.